Ancora Biotech
Latest round
- Series A
Last raised
- Jun 2022
Total raised
- $60M
Investors
- 2
About Ancora Biotech
a. Ancora Biotech operates as a biopharmaceutical company that intends to develop antibody biotherapeutics drugs intended to develop a treatment for several life-threatening diseases. The company’s product line includes TeneoTwo’s TNB-486, an antibody biotherapeutic drug in phase I clinical studies for the treatment of B-cell malignancies; TeneoFour’s TNB-738, an antibody biotherapeutic drug in phase I clinical studies for the treatment of metabolic and inflammatory diseases; and TeneoTen’s anti-HBVxCD3, an antibody biotherapeutic drug for the treatment of chronic hepatitis B (CHB).
Who invested in Ancora Biotech
2 investors across 1 round
See all investors in Ancora Biotech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jun 9, 2022
Amount
$60M
Investors
Questions about Ancora Biotech
Who invested in Ancora Biotech?
Ancora Biotech has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ancora Biotech raised?
Ancora Biotech has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Ancora Biotech last raise money?
Ancora Biotech's most recent round on record is a Series A, in Jun 2022.
What does Ancora Biotech do?
Ancora Biotech is a biotechnology company.
Where is Ancora Biotech headquartered?
Ancora Biotech is headquartered in Palo Alto, US.
Which VCs invest in companies like Ancora Biotech?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Ancora Biotech's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Ancora Biotech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.